The New Heartland Advisors Inc Holding in Interpace Diagnostics Group, Inc
Heartland Advisors Inc filed with the SEC SC 13G form for Interpace Diagnostics Group, Inc. The form can be accessed here: 000089271216001941. As reported in Heartland Advisors Inc’s form, the filler as of late owns 14.8% or 2,681,345 shares of the Health Care–company.
Interpace Diagnostics Group, Inc stake is a new one for the for this institutional investor and it was filed because of activity on October 14, 2016. We feel this shows Heartland Advisors Inc’s positive view for the stock. For a institutional investor managing $6.06 billion in assets and having 51+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.
Interpace Diagnostics Group, Inc Institutional Sentiment
Latest Security and Exchange filings show 20 investors own Interpace Diagnostics Group, Inc. The institutional ownership in Q3 2015 is low, at 33.33% of the outstanding shares. This is decreased by 359648 the total institutional shares. 6051831 were the shares owned by these institutional investors. In total 2 funds opened new Interpace Diagnostics Group, Inc stakes, 8 increased stakes. There were 5 that closed positions and 1 reduced them.
Grt Capital Partners Llc is an institutional investor bullish on Interpace Diagnostics Group, Inc, owning 108790 shares as of Q3 2015 for 0.05% of its portfolio. Amg National Trust Bank owns 21874 shares or less than 0.01% of its portfolio. PA Minerva Advisors Llc have 0.03% of their stock portfolio for 22195 shares. Further, Heartland Advisors Inc reported stake worth 0.21% of its US stock portfolio. The X1 Ancora Advisors Llc owns 302900 shares. Interpace Diagnostics Group, Inc is 0.07% of the manager’s US portfolio.
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.
Heartland Advisors Inc website.
It is down 6.00% since September 19, 2016 and is uptrending. It has outperformed by 0.46% the S&P500.
More notable recent POWERSHARES FTSE RAFI (SWX:PDII) news were published by: Prnewswire.com which released: “Invesco PowerShares Celebrates 10th Anniversary of First Smart Beta Portfolio …” on December 09, 2015, also Seekingalpha.com with their article: “Selecting An Emerging Markets Value ETF” published on December 31, 2014, Benzinga.com published: “An ETF That Cements The Case For Smart Beta” on March 01, 2016. More interesting news about POWERSHARES FTSE RAFI (SWX:PDII) were released by: Forbes.com and their article: “Has Rob Arnott Built A Better Index Fund?” published on June 05, 2013 as well as Seekingalpha.com‘s news article titled: “Why These Fundamental ETFs Should Make Up Your Core Portfolio” with publication date: February 26, 2013.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.